

Special Issue

IgA, IgG and Cell-Mediated Immunity: A Comprehensive Understanding of Effective Respiratory Syncytial Virus (RSV) Vaccines

Message from the Guest Editor

Considering the complexity of RSV vaccination targets, which include infants, pregnant women and the elderly, we think it is time to summarize the experiences on the development of RSV vaccines based on non-inactivated technologies, in particular, those which can avoid immunopathology in infants, and those which may induce a high rate of protection and long-lasting efficacy in the elderly. In this Special Issue, contributions in the form of original research or reviews, including, but not limited to, the following topics are welcome: (i) basic research on RSV invasion and immunopathology; (ii) vaccine immunization strategies; (iii) vaccine antigen prefusion protein design; (iv) adjuvant effects to elevate vaccine efficacy and to lower the risk of immunopathology; and (v) strategies to avoid antibody decline and prolong vaccine efficacy.

Guest Editor

Dr. Cunbao Liu

Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China

Deadline for manuscript submissions

closed (30 September 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/138600

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).